Revolution Medicines, Inc. 8-K

What Happened

• Revolution Medicines (RVMD) announced that Steve Kelsey, M.D., FRCP, FRCPath, intends to retire from employment effective January 4, 2027. He will transition from President, Research & Development to Senior Advisor to the CEO effective July 1, 2026. The company said it currently contemplates appointing Dr. Kelsey to its board of directors upon his retirement, subject to board approval.
• The company also reported results from its June 18, 2026 annual meeting of stockholders (record date: April 23, 2026; 212,592,561 shares outstanding).

Key Details

• Executive transition: Dr. Kelsey moves to Senior Advisor on July 1, 2026; retirement effective January 4, 2027; eligible for retirement benefits under the company’s equity award retirement policy. Board appointment upon retirement is contemplated but not yet approved.
• Director elections (Class III): Alexis Borisy — For: 127,181,172; Withheld: 33,660,532; Broker non-votes: 20,813,641. Mark A. Goldsmith, M.D., Ph.D. — For: 157,681,628; Withheld: 3,160,076; Broker non-votes: 20,813,641.
• Auditor ratification: PricewaterhouseCoopers LLP ratified as independent auditor — For: 181,309,783; Against: 206,306; Abstentions: 139,256.
• Advisory vote on executive compensation (say-on-pay): For: 155,110,825; Against: 5,554,146; Abstentions: 176,733; Broker non-votes: 20,813,641.

Why It Matters

• Leadership continuity: The planned transition keeps Dr. Kelsey involved through year-end 2026 and preserves his institutional knowledge while the company contemplates a board role, which may affect R&D leadership planning and investor perceptions.
• Governance & oversight: The director elections and auditor ratification were approved by shareholders, and the strong say-on-pay support signals general investor support for executive compensation as disclosed.
• Timing and uncertainty: The company’s statements are forward-looking — the retirement date, role transition, and board appointment remain subject to change and board approval; investors should watch subsequent disclosures for final confirmations.